StockpollyBeta
ChatSearch/
Get AppSign in
Menu
Sign in
CategoryChatSearchMaster portfoliosResearch firmsBlog
Markets
Global MarketsHeatmapAI MapScreener
Tools
P/E CompareComparePortfolio
Company
AboutPricing
ContactFeedback
AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions
momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks
PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12
Popularity #2,825
LTGO · NASDAQ · Medical - Pharmaceuticals

Latigo Biotherapeutics (LTGO)

LTGO

Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.

$20.09
vs last close−0.73 (−3.49%)
OverviewEarningsFinancialsOwnershipNews

News type

  1. Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

    Defense WorldSep 9Other

  2. Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

    GlobeNewsWireSep 3Earnings

  3. Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

    24/7 Wall StreetAug 13

  4. Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares

    Defense WorldAug 11

  5. Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares

    Defense WorldAug 11

  6. Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain

    Business WireJul 29

β 1.24briefsthe tapeclosesdividendstranscriptswiresliquidityclosesminutesYoY +18%threadsTSLAthreadsthreadsmarginsafter-hrstranscriptsmomentumVIX 14.2minutesrumorsupgradesQ3estimatesnewsflowbuybacksPCEthreadsvolatility13Fnarrativesflowsmomentumdowngradesyield curvesDXYdowngradessessions52w hiheadlinesyield curvesdowngradessentimentvolatilityyield curvesrumorsβ 1.24volumesfuturesforecaststickerspre-mktforecastschatterliquidityEPS 4.12newsflownoisedrawdownsGOOGLupgradesconsensuswires8-KliquidityconsensuswhispersMSFTheadlinespositioningbriefsthreadsEPS 4.12guidanceminutesnewsflow+0.8%cyclesestimates+2.41%marginsmarginsthreads2s10sliquiditycyclesnarrativesrumorsbuybacksvolumesPMI 52.1cycleschatter2s10stranscriptsconsensusmargins
GDPclosesYoY +18%buybacksnewsflow13FrevisionsflowsT+1positioningrevisionsnewsflowconsensusvolumesfilingsAAPLfuturesYoY +18%futuresmarginsflowsvolatilityrevisionsDXYwhispersearnings callspositioningAVGOcatalystsyield curvesMETA10-Kconsensus
P/E 28.4catalystsspx 0dtecatalystsbid/askvolatilityheadlinesguidancedrawdowns
Stockpolly
An agent-based financial analysis engine for public markets.
© 2026 Stockpolly. All rights reserved.
Company
AboutPricing
Legal
TermsPrivacy
Support
ContactFeedback